| Genomic Medicine |
1 |
1 |
| Epidermal Growth Factor Receptor |
0 |
0.83 |
| Lung Cancer |
0 |
0.66 |
| Biologic Therapy |
0 |
0.62 |
| Chemotherapy |
0 |
0.39 |
| Toxicology |
0 |
0.39 |
| Combination Chemotherapy |
0 |
0.3 |
| Small Cell Lung Cancer |
0 |
0.22 |
| Vascular Endothelial Growth Factor |
0 |
0.21 |
| Antineoplastic Drug |
0 |
0.2 |
| Humanized Monoclonal Antibody |
0 |
0.2 |
| Non-Small Cell Lung Cancer |
0 |
0.99 |
| Targeted Cancer Therapy |
0 |
0.2 |
| Monoclonal Antibody |
0 |
0.18 |
| Quality of Life |
0 |
0.18 |
| Tyrosine Kinase Inhibitor |
0 |
0.15 |
| Cancer |
0 |
0.14 |
| Lung |
0 |
0.14 |
| Angiogenesis Inhibitors |
0 |
0.07 |
| Clinical Research |
0 |
0.04 |
| Immunotherapy |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Tyrosine Kinase |
0 |
0.04 |